Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum

Clicks: 16
ID: 332331
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #40 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims To evaluate the association between beta-blocker (BB) prescription and long-term all-cause mortality after acute coronary syndrome (ACS), and to assess whether this varies across the left ventricular ejection fraction (LVEF) spectrum. Methods We analysed ACS patients from the retrospective multicentre CardioMining study (NCT05176769). The primary analysis used inverse probability of treatment weighting (IPTW) and restricted mean survival time (RMST) derived from weighted Kaplan-Meier curves. RMST and survival differences were estimated at 1 and 5 years. A landmark analysis evaluated survival between years 1 and 5 among first-year survivors. Results Among 6,049 ACS patients (age 66.8±13.2 years; 74.9% male), 5,107 (84.4%) were discharged on BBs. During a median 4.6-year follow-up, 1,912 deaths (31.6%) occurred. Overall, the 1-year RMST difference associated with BBs was 6.3 days (95%CI 0.0 to 13.2), which attenuated further by 5 years (11.3 days, 95%CI -30.7 to 63.9). The largest 1-year RMST difference was observed among patients with LVEF≤40% (18.8 days, 95%CI 1.1 to 37.4), whereas associations were smaller and non-significant among patients with LVEF 41-49% and LVEF≥50%. At 5 years, confidence intervals crossed the null across all LVEF categories. Continuous LVEF analyses suggested greater short-term benefit at lower values, with progressive attenuation across the LVEF spectrum. Among 1-year survivors, no significant RMST differences were observed between years 1 and 5. Conclusion Discharge BB prescription was not associated with a clear long-term survival advantage after ACS in this large real-world cohort. Apparent associations were strongest at lower LVEF values and attenuated during longer follow-up.
Reference Key
openalex_W7221754324 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eirinaios Tsiartas, Sokratis Oikonomou, Aristea Iordanidou, Athanasios Samaras, Αndreas S. Papazoglou, Dimitrios V. Moysidis, Vassilios Pericles Vassilikos, Antonios Ziakas, Periklis A. Davlouros, Konstantinos P Tsioufis, Dimitrios N. Tziakas, Ιoannis Zarifis, George A. Giannakoulas
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag175
URL
https://doi.org/10.1093/ehjopen/oeag175
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.